COMPANY
Kodiak Sciences
Ursus, Kodiak’s custom commercial scale manufacturing facility designed for complex antibody conjugate biotherapies, is successfully commissioned as a cGMP facility for Kodiak’s ABCD medicines. From company website Source · Oct 12, 2026
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior IT / Security Engineer | Location not stated | Not stated | Oct 16, 2026 |
| Director, Biostatistics | Location not stated | Not stated | Oct 11, 2026 |
| Senior Manager / Manager, Clinical Data Management | Location not stated | Not stated | Oct 11, 2026 |
| Polymer Chemist | Location not stated | Not stated | Oct 11, 2026 |
| Scientist, Organic Chemistry | Location not stated | Not stated | Oct 11, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 3 trial (NCT07734844, actual start Aug 3, 2026); 2 clinical-operations roles open. ClinicalTrials.gov NCT07734844 (Aug 3, 2026)
Evidence (1 event)
- Aug 3, 2026 · ClinicalTrials.gov NCT07734844
leadSponsor.name='Kodiak Sciences Inc'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-03,type:ACTUAL}; studyFirstPostDate=2026-07-29; briefTitle='A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO'
- Aug 3, 2026 · ClinicalTrials.gov NCT07734844
Timeline
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO source ↗
- Trial start 3: A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK source ↗
- Trial start 3: A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAM source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) source ↗
- Trial start Phase 3: A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) source ↗
- Trial start Phase 2/Phase 3: A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degenerat source ↗
- Trial start Phase 1: Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subje source ↗
Upcoming milestones
- 2027-02 (ESTIMATED) · 3 · A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE · NCT06996080
- 2027-04 (ESTIMATED) · 3 · A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK · NCT06990399
- Aug 31, 2028 (ESTIMATED) · Phase 3 · A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO · NCT07734844
Clinical trials (lead sponsor) 12
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07734844 | A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO | Phase 3 | Recruiting | Aug 3, 2026 | Aug 31, 2028 (estimated) |
| NCT06996080 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | 3 | Recruiting | Jul 16, 2025 | 2027-02 (estimated) |
| NCT06990399 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | 3 | Recruiting | Jul 30, 2025 | 2027-04 (estimated) |
| NCT06270836 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) | Phase 3 | Completed | May 1, 2024 | Feb 13, 2026 (actual) |
| NCT06556368 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Phase 3 | Active, not recruiting | Aug 23, 2024 | 2026-08 (estimated) |
| NCT05066230 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) | Phase 3 | Terminated | Sep 7, 2021 | Aug 3, 2023 (actual) |
| NCT04611152 | A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) | Phase 3 | Terminated | Sep 30, 2020 | May 11, 2023 (actual) |
| NCT04603937 | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) | Phase 3 | Terminated | Sep 30, 2020 | Apr 27, 2023 (actual) |
| NCT04049266 | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. | Phase 2/Phase 3 | Terminated | Oct 8, 2019 | Nov 17, 2021 (actual) |
| NCT04964089 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) | Phase 3 | Completed | Jun 23, 2021 | Mar 28, 2023 (actual) |
| NCT04592419 | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) | Phase 3 | Completed | Sep 25, 2020 | Jun 10, 2022 (actual) |
| NCT03790852 | Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO | Phase 1 | Terminated | Dec 26, 2018 | Jun 2, 2021 (actual) |
Open jobs 10
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Senior IT / Security Engineer | Not listed | Not stated | Oct 16, 2026 | Not stated |
| Director, Biostatistics | Not listed | Not stated | Oct 11, 2026 | Not stated |
| Senior Manager / Manager, Clinical Data Management | Not listed | Not stated | Oct 11, 2026 | Not stated |
| Polymer Chemist | Not listed | Not stated | Oct 11, 2026 | Not stated |
| Scientist, Organic Chemistry | Not listed | Not stated | Oct 11, 2026 | Not stated |
| Senior Electrical Engineer — VETi Platform | Not listed | Not stated | Oct 11, 2026 | Not stated |
| Senior Optical Engineer — VETi Platform | Not listed | Not stated | Oct 11, 2026 | Not stated |
| Senior Software Engineer — VETi Platform | Not listed | Not stated | Oct 11, 2026 | Not stated |
| Associate Director, Quality Operations | Not listed | Not stated | Oct 11, 2026 | Not stated |
| Research Associate, Quality Operations | Not listed | Not stated | Oct 11, 2026 | Not stated |
Connect
See your connections at Kodiak Sciences on LinkedIn (search by name, results not checked)